M&A / Deals Roche looks to Astex in $515m breast cancer deal PharmaphorumRoche's Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer.OncologyRead full story pharminent July 6, 2026 (Last updated: July 7, 2026) Pharmaphorum Roche’s Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer. Oncology Read full story Post navigation Previous: Wegovy pill launches in UK as first daily oral GLP1 for weight managementNext: Novartis to acquire Myricx Bio in up to $1.5bn deal Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026